Amylyx Pharmaceuticals Overview
Valuation check: AMLX's P/E ratio is -27.42, below the sector sector average of 34.56.
Get informed when a big investor buys or sells
+ Follow-27.42
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Amylyx Pharmaceuticals (AMLX) currently reports a P/E ratio of -27.42. That is below the sector sector average of 34.56. Use the charts on this page to explore Amylyx Pharmaceuticals's P/E ratio history and peer comparisons.
Amylyx Pharmaceuticals's P/E ratio of -27.42 is lower than the its sector sector average of 34.56. That is roughly 179.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Amylyx Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -27.42, AMLX can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -27.42, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 34.56. From there, open related valuation or income-statement pages for Amylyx Pharmaceuticals, and consider following AMLX for alerts when major investors trade the stock.
